HWN Suggests

From NASH to MASH: Unraveling the Evolution and Future of Liver Disease Treatment

In the ever-evolving world of liver disease, the shift from Nonalcoholic Steatohepatitis (NASH) to Metabolic Associated Steatotic Hepatitis (MASH) marks a revolutionary leap in our understanding and approach to treatment. This transition isn’t merely a rebranding; it signifies a profound recognition of the intricate dance between metabolic dysfunction and liver health. As obesity and metabolic disorders increasingly take center stage in public health, MASH emerges as a clarion call for a deeper dive into the metabolic roots of liver disease. Understanding the transition from NASH to MASH, alongside the evolving drug therapies, is vital for healthcare providers and patients navigating these complex…

read full article

Featured

  From NASH to MASH

Nonalcoholic steatohepatitis (NASH) is now metabolic dysfunction-associated steatohepatitis (MASH), the most severe form of MASLD characterized by lipotoxicity and inflammatory damage to hepatocytes resulting from a metabolic disorder such as obesity or diabetes.

  MASH (Formerly NASH): Understanding This Form of Fatty Liver Disease

One condition that overnutrition can lead to is MASH (metabolic dysfunction-associated steatohepatitis). Formerly known as NASH, MASH is a form of nonalcoholic liver disease, which describes a spectrum of conditions marked by fat buildup in the liver not caused by alcohol use. “With MASH, the liver ends up storing these excess nutrients and you get both fat as well as inflammation of the liver,” says Vikas Gupta, MD, PhD, clinical director of the Yale Fatty Liver Disease Program. “If you let that fat and inflammation go inside of the liver for long periods of time, that scar tissue starts to build up and can lead to cirrhosis of the liver.”

Articles of Interest

A Common Weight Loss Drug Can Treat Severe Liver Disease, F.D.A. Says

Wegovy has been approved for use among the growing number of Americans who have MASH.

Wegovy Could Treat Another Chronic Disease

A large trial showed that the weight-loss drug could reduce liver inflammation and scarring caused by a common condition.

Diabetes and obesity can damage the liver to the point of failure – but few people know their risk of developing liver disease

MASH can be difficult to diagnose because it either causes no symptoms or can be mistaken for other conditions. Patients may have the condition for years and not be aware that it is slowly and meticulously causing damage. In that sense, MASH is strikingly similar to type 2 diabetes or high cholesterol.

MASH 101: What You Need to Know About an Emerging Liver Disease

Read or hear the words “liver disease” and most people probably think of alcohol-associated liver disease: the fatty liver, hepatitis and cirrhosis that can develop among people who drink excessively, usually over a long period of time. But did you know there are serious liver diseases that are not linked to alcohol consumption? One is metabolic dysfunction-associated steatotic liver disease (MASLD), a condition in which fat builds up in the liver. The more severe form of the disease is called MASH, or metabolic dysfunction-associated steatohepatitis, a dangerously progressive form of MASLD in which patients have inflammation of the liver and liver damage in addition to excess fat. Cirrhosis (scar buildup) can develop if MASH advances.

MASH Driving Global Epidemic of Primary Liver Cancer

The burden of MASH-associated primary liver cancer (PLC) is rising rapidly while, thanks to effective suppressive treatments, the incidence of PLC from viral hepatitis is declining.

Renamed, common liver diseases might get fairer shake at treatment, researchers hope

About 20% of those with MASLD are thought to have a more severe form of the disease, marked by liver scarring and inflammation. (That subcategory, non-alcoholic steatohepatitis, better known as NASH, is now called metabolic dysfunction-associated steatohepatitis, or MASH.)

Resources

10 Causes or Contributing Factors for MASLD and MASH

Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic dysfunction-Associated Steatohepatitis (MASH) are relatively new terms in the medical lexicon, particularly evolving from a better understanding of liver diseases traditionally categorized under Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic SteatoHepatitis (NASH).

MASH Awareness

Often considered a "silent" disease, MASH can go unaddressed, which can lead to serious consequences. Early intervention is essential for long-term management—yet the majority of US cases are undiagnosed.

myMASHteam

myMASHteam is the social network for those living with metabolic dysfunction-associated steatohepatitis (MASH). Get the emotional support you need from others like you, and gain practical advice and insights on managing treatment or therapies for MASH. myMASHteam is the only social network where you can truly connect, make real friendships, and share daily ups and downs in a judgement-free place.

NASHNET

NASHNET is a global network of thought leaders dedicated to innovating nonalcoholic steatohepatitis (NASH) care delivery, featuring a network of affiliated health systems and industry partners. NASHNET promotes the discovery, development and optimization of care pathways and interventions that align key stakeholders, ensure appropriateness of and linkage to care, and enhance the patient experience. Since NASHNET was founded in 2016, we have been growing our diverse network of high-performing, population health-focused member organizations. We recognized a need for improved NASH care delivery, including identifying patients earlier in their disease progression. Nonalcoholic fatty liver disease (NAFLD) affects more than 30 percent of adults in the United States, and it is among the most common causes of liver disease. If not diagnosed or managed, NAFLD can cause liver fibrosis and progress to NASH or liver cirrhosis.